Page last checked
Comparison · sourced side by side
Survodutide vs Tirzepatide
The sources here do not include a direct trial of survodutide against tirzepatide. Each drug was tested in its own study, with different people and follow-up times. The gap between those results does not show how the drugs compare. Read each study’s doses, results and limits below.
Human trial FDA label
What matters first
- Head-to-head evidence
- No direct trial
- Survodutide record
- Human trial; 1 sourced dose row
- Tirzepatide record
- FDA label; 2 sourced dose rows
Is there a head-to-head trial?
Each result can still be read on its own. Both appear below with their own citations, but not on one shared chart.
Side by side
Compare approved uses, studied doses and reported effects. Missing information is labeled, and the sources for the clinical figures appear below.
| Property | Survodutide | Tirzepatide |
|---|---|---|
| Drug class | Glucagon/GLP-1 dual receptor agonist (investigational) | GIP/GLP-1 dual receptor agonist |
| Brand names | None — no approved product | Zepbound, Mounjaro |
| FDA approval | Not approved — investigational | Approved |
| Strongest source | Human trial | FDA label |
| Dosing | 0.6–4.8 mg | 5–15 mg |
| Half-life | Not recorded | ≈ 5 days |
| Boxed warning | None on record | Risk of thyroid C-cell tumors |
| Reactions on record | 4 | 15 |
| Typical vial sizes | 5 mg · 10 mg | 5 mg · 10 mg · 15 mg · 30 mg · 60 mg |
4Comparison details
How they work differently
Survodutide is a glucagon/glp-1 dual receptor agonist. Tirzepatide is a gip/glp-1 dual receptor agonist. They switch on different signals in the body. That can change both benefits and side effects. Even with a shared target, one drug cannot simply take the place of the other.
More targets do not guarantee a better result. They change both the effect and the side-effect pattern. A clinician weighs those tradeoffs for each person.
Side effects compared
Side effects below come from each compound’s own page, grouped by whether both records list them. A side effect on one list only means the other record does not carry it — not that it never happens.
Regulatory status compared
Survodutide
FDA has not approved survodutide, also called BI 456906.
Phase 3 SYNCHRONIZE trials study obesity. A separate phase 2 program studies MASH, a form of liver disease. No dosing label exists, and any product sold today is unapproved.
The doses here describe study groups, not advice.
Tirzepatide
FDA-approved as branded pens.
Compounded tirzepatide now faces tight limits. FDA declared the shortage over in late 2024. It has proposed dropping tirzepatide from the 503B bulks list.
That leaves one narrow lane: 503A compounding for a named patient with a documented clinical need.
Keep reading
Open the individual drug guides for full dose schedules, study details and related tools.
What the sources say about survodutide, beyond Survodutide vs tirzepatide
Tirzepatide on its own page, outside Survodutide vs tirzepatide
Work out a tirzepatide draw, one side of Survodutide vs tirzepatide
The survodutide calculator behind Survodutide vs tirzepatide
The survodutide schedule that Survodutide vs tirzepatide summarizes
Tirzepatide dosing in full, beyond Survodutide vs tirzepatide
Mixing math for any peptide, with Survodutide vs tirzepatide as one example
More options to compare after Survodutide vs tirzepatide
The dated regulatory page behind Survodutide vs tirzepatide
How both pages in Survodutide vs tirzepatide were source-checked
Common questions
Which is more effective, survodutide or tirzepatide?
The cited studies do not answer that directly. Each drug was studied separately, so subtracting their results does not show how they would compare in the same trial.
Can these two be compared using their separate trial results?
Not reliably. The people, time span and goals can differ from trial to trial. A head-to-head trial tests both drugs in the same study.
Are the side-effect profiles the same?
Both records list 2 of the same side effects, mostly gut symptoms. Their full lists and study groups differ, so matching names do not mean matching rates.
Is either one approved by the FDA?
Tirzepatide is FDA-approved and has a prescribing label. Survodutide is still experimental, has no approved label, and anything sold today is unapproved.
Does a newer compound mean a better one?
No. A newer drug often has less evidence, a shorter safety record, and no approved label. The strength of the evidence above is more useful than age alone.
Can someone switch between them?
A prescriber needs to consider the reason for treatment, current dose and response before planning a change.
Questions readers ask
Is anything better than tirzepatide?
Is anything better than tirzepatide?
SURMOUNT-5 found greater average weight loss with tirzepatide than with semaglutide: 20.2% versus 13.7% after 72 weeks.
Survodutide was not part of that trial. Its separate phase 2 result cannot establish whether it works better or worse than tirzepatide.
When will survodutide be approved?
When will survodutide be approved?
The trial sources on this page do not establish an FDA approval date for survodutide. A trial schedule is not an approval schedule.
Study results can support an application, but they do not guarantee approval or establish a prescribing dose.
How effective is survodutide for weight loss?
How effective is survodutide for weight loss?
In the 46-week phase 2 trial, 387 people were assigned to survodutide or placebo. Average weight change ranged from −6.2% to −14.9% across the four drug groups, versus −2.8% with placebo.
The trial tested different doses against placebo. It did not compare survodutide with tirzepatide.
Is tirzepatide going to be discontinued?
Is tirzepatide going to be discontinued?
The Mounjaro and Zepbound labels reviewed for this comparison still list tirzepatide. Those labels do not announce that the manufacturer is stopping these products.
A current label does not guarantee stock at a pharmacy. Availability and a manufacturer’s decision to stop a product are different questions.
- le Roux CW et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: dose-finding phase 2 trial. Lancet Diabetes Endocrinol 2024 (PMID 38330987)retrieved 2026-08-20Human trial
- Zepbound (tirzepatide) — FDA-approved Prescribing Informationretrieved 2026-09-19FDA label